


Global Biosimilar Market: Trends & Opportunities (2014-2018)

January 2015



Global Biosimilar Market Report

Scope of the Report

The report titled “Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of global biosimilar market (Recombinant Glycosylated Biosimilars and Recombinant Non-Glycosylated Biosimilars) with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall Biosimilar Market has also been forecasted for the period 2014-18, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Also, growth of the Recombinant Glycosylated Biosimilars and Recombinant Non-Glycosylated Biosimilars are forecasted. Further, key players of the industry like Sandoz, Hospira, Teva and Dr. Reddy’s Lab are analyzed in the report.

Segment Coverage

- ⊕ Recombinant Glycosylated Biosimilars(EPO,mAb,Follitropin)
- ⊕ Recombinant Non-Glycosylated Biosimilars(Insulin,G-csf,Interferons,hGh)

Company Coverage

- ⊕ Sandoz(Novartis)
- ⊕ Hospira
- ⊕ Teva
- ⊕ Dr. Reddy’s Lab

Global Biosimilar Market Report

Executive Summary

Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conducive government initiatives and rising incidences of various diseases are significant factors that are facilitating the growth of global biosimilar market.


On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth. Emerging pharmaceutical market and less stringent government regulatory frameworks in few countries can provide some of the major opportunities for Biosimilars market. In addition, increased collaboration between manufacturing companies and outsourcing of biosimilar products are key trends in the biosimilar market.

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Globally there are 280 Biosimilars in pipeline and their clinical trials are increasing at a rate of 20% annually.


Global Biosimilars Market: An Overview

The global biosimilar market is expected to reach...in 2018, growing at CAGR of The growth is attributed to the rise in the ongoing patent expirations of biologic drugs . In 2012, the global biosimilar market amounted toand grew byto reachin 2013. The growth was slower than the previous year in which market grew byfrom 2011 to reach Billion in 2012

Global Biosimilar market:2014-2018-(U.S\$ Billion)




Biosimilar products market share in %



Global Biosimilar Market: Product Analysis

The biosimilar market will grow to U.S\$..... billion in 2018. U.S\$....billion is expected to generate from recombinant non-glycosylated biosimilars and recombinant glycosylated biosimilars will account for U.S\$..... billion

Biosimilar recombinant non-glycosylated Market (2014-2018) –U.S\$ Billion



Biosimilar recombinant non-glycosylated Market (2014-2018) –U.S\$ Billion

